Posted on Mörfelden-Walldorf

Cansativa digitizes an official patient verification for Medical Cannabis

For the first time, Cansativa Group is testing a fully digitized patient verification system for medical cannabis. Patients are given the opportunity to prove that they are in lawful possession of medical cannabis by means of a QR code on their smartphone. The principle of this solution is already familiar to most people through the German digital COVID certificate. Despite existing certificates, patients have so far lacked effective and innovative solutions to prove possession of medical cannabis in a legally secure manner. The problem is that law enforcement authorities often do not accept the provisional IDs issued by companies and associations as legitimate proof. This increases the pressure of suffering for patients and regularly presents police and customs with operational challenges.

To address this problem, Cansativa has worked with technology provider UBIRCH and partners to develop a secure and privacy-friendly proof of vaccination whose technology has already proven itself with millions of users. In the Corona pandemic, UBIRCH worked with partners on behalf of the German Federal Ministry of Health to develop the solution for forgery-proof digital verification of vaccination that does not require a central registry.

The digital patient record is created directly at the time of purchase of medical cannabis in the pharmacy in a data-saving process and can be checked by authorities in an uncomplicated manner. This way, stigmas surrounding cannabis patients can be reduced and safe handling of medical cannabis becomes facilitated.

With this solution, the Cansativa Group creates an essential interface in patient contact and contributes to the digitization of the German healthcare system by applying secure and tested technologies. The solution will be put to test with different stakeholders in the industry over the next few weeks and will soon be available for pharmacies in the beta phase. Further information is available via:

About Cansativa Group

Cansativa Group is the market leader in the medical cannabis market and sees itself as the driving force behind the young cannabis industry in Germany. Since the award of the Federal Institute for Drugs and Medical Devices (BfArM) in August 2020, they are the only company with approval for the distribution of medical cannabis from German cultivation. In the upcoming cannabis legalization, Cansativa Group sees itself as a pioneer in the democratization of the cannabis market. They import, store, license, distribute, supply, brand and educate.

Press Contact
Hannah Bellmann | Public Relations | Cansativa Group
+49 157 377 449 33 or

Press release